Saurashtra News

Peripheral T-Cell Lymphomas Pipeline as Novel and Extensive 40+ Therapies Likely to Enter in the Treatment Domain

 Breaking News
  • No posts were found

Peripheral T-Cell Lymphomas Pipeline as Novel and Extensive 40+ Therapies Likely to Enter in the Treatment Domain

December 08
11:16 2022
Peripheral T-Cell Lymphomas Pipeline as Novel and Extensive 40+ Therapies Likely to Enter in the Treatment Domain

DelveInsight’s, “Peripheral T-Cell Lymphomas Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Peripheral T-Cell Lymphomas Pipeline

  • DelveInsight’s Peripheral T-Cell Lymphomas Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Peripheral T-Cell Lymphomas.
  • The leading Peripheral T-Cell Lymphomas Companies are working include Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others.
  • Promising Peripheral T-Cell Lymphomas Pipeline Therapies include Belinostat, Pralatrexate Injection, HBI-8000, Chidamide, cyclophosphamide, Duvelisib, KW-0761 (mogamulizumab), Romidepsin, E7777, SP-02L (darinaparsin for injection), and others.
  • The Peripheral T-Cell Lymphomas Companies and academics are working to assess challenges and seek opportunities that could influence Peripheral T-Cell Lymphomas (PTCL) R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral T-Cell Lymphomas (PTCL).

 

Recent Developmental Activities in the Peripheral T-Cell Lymphomas Pipeline

  • The novel epigenetic drug, HBI-8000, is a member of the benzamide class of histone deacetylase inhibitors (HDACIs), working by controlling how tightly DNA is wound around histone proteins, which regulate gene expression. This alters the expression of several proteins involved in processes that arrest the growth of cancer cells, increase tumor immunity and change the tumor microenvironment. Evidence suggests that this mechanism increases the efficacy of other cancer agents such as checkpoint inhibitors.

 

Request a sample and discover the recent advances in Peripheral T-Cell Lymphomas Treatment Drugs @ Peripheral T-Cell Lymphomas Pipeline Outlook Report

 

Peripheral T-Cell Lymphomas Overview

Peripheral T-Cell Lymphomas (PTCL) is defined as a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. Peripheral T-Cell Lymphomas (PTCL) is classified as a subtype of non-Hodgkin’s lymphoma (NHL). NHL affects two particular types of white blood cells: B-cells and T-cells. Peripheral T-Cell Lymphomas (PTCL) specifically affects T-cells, and results when T-cells develop and grow abnormally.

 

Peripheral T-Cell Lymphomas Emerging Drugs Profile

  • HBI-8000: HUYA Bioscience International

 

Peripheral T-Cell Lymphomas Pipeline Report

In the Peripheral T-Cell Lymphomas pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral T-Cell Lymphomas collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Get an overview of the Peripheral T-Cell Lymphomas Pipeline Report @ Peripheral T-Cell Lymphomas Ongoing Clinical Trials Analysis

 

Scope of the Peripheral T-Cell Lymphomas Pipeline Report

  • Coverage- Global
  • Peripheral T-Cell Lymphomas Companies are working include Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others
  • Peripheral T-Cell Lymphomas Pipeline Therapies include Belinostat, Pralatrexate Injection, HBI-8000, Chidamide, cyclophosphamide, Duvelisib, KW-0761 (mogamulizumab), Romidepsin, E7777, SP-02L (darinaparsin for injection), and others
  • Peripheral T-Cell Lymphomas Emerging Drugs, Unmet Needs, Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Peripheral T-Cell Lymphomas (PTCL): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Peripheral T-Cell Lymphomas (PTCL) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Peripheral T-Cell Lymphomas (PTCL) Collaboration Deals
  9. Mid Stage Products (Phase II)
  10. HBI-8000: HUYA Bioscience International
  11. F520: Shandong New Time Pharmaceutical Co., LTD
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. YY-20394: Shanghai YingLi Pharmaceutical Co. Ltd.
  15. Drug profiles in the detailed report…..
  16. Pre-clinical and Discovery Stage Products
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Peripheral T-Cell Lymphomas (PTCL) Key Companies
  20. Peripheral T-Cell Lymphomas (PTCL) Key Products
  21. Peripheral T-Cell Lymphomas (PTCL)- Unmet Needs
  22. Peripheral T-Cell Lymphomas (PTCL)- Market Drivers and Barriers
  23. Peripheral T-Cell Lymphomas (PTCL)- Future Perspectives and Conclusion
  24. Peripheral T-Cell Lymphomas (PTCL) Analyst Views
  25. Peripheral T-Cell Lymphomas (PTCL) Key Companies
  26. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Peripheral T-Cell Lymphomas (PTCL) drugs?
  • How many Peripheral T-Cell Lymphomas (PTCL) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral T-Cell Lymphomas (PTCL)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral T-Cell Lymphomas (PTCL) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peripheral T-Cell Lymphomas (PTCL) and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Peripheral T-Cell Lymphomas Pipeline therapeutics, reach out to Peripheral T-Cell Lymphomas Treatment Landscape

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles